California Public Employees Retirement System held its stake in VIVUS, Inc. (NASDAQ:VVUS) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 112,000 shares of the biopharmaceutical company’s stock at the end of the 2nd quarter. California Public Employees Retirement System owned approximately 0.11% of VIVUS worth $137,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Spark Investment Management LLC acquired a new stake in shares of VIVUS during the second quarter worth about $100,000. Bank of New York Mellon Corp increased its position in shares of VIVUS by 3.6% during the first quarter. Bank of New York Mellon Corp now owns 106,842 shares of the biopharmaceutical company’s stock worth $120,000 after purchasing an additional 3,694 shares in the last quarter. Russell Investments Group Ltd. increased its position in shares of VIVUS by 84.8% during the second quarter. Russell Investments Group Ltd. now owns 148,600 shares of the biopharmaceutical company’s stock worth $180,000 after purchasing an additional 68,200 shares in the last quarter. Northern Trust Corp increased its position in shares of VIVUS by 16.8% during the second quarter. Northern Trust Corp now owns 275,097 shares of the biopharmaceutical company’s stock worth $335,000 after purchasing an additional 39,473 shares in the last quarter. Finally, Acadian Asset Management LLC increased its position in shares of VIVUS by 70.9% during the second quarter. Acadian Asset Management LLC now owns 1,837,822 shares of the biopharmaceutical company’s stock worth $2,241,000 after purchasing an additional 762,392 shares in the last quarter. 31.35% of the stock is owned by institutional investors.

Separately, ValuEngine upgraded VIVUS from a “hold” rating to a “buy” rating in a research report on Monday, October 2nd.

Shares of VIVUS, Inc. (VVUS) opened at $0.63 on Monday. The company has a current ratio of 7.47, a quick ratio of 7.09 and a debt-to-equity ratio of 643.86. VIVUS, Inc. has a 52-week low of $0.61 and a 52-week high of $1.47. The company has a market capitalization of $67.28, a PE ratio of 1.87 and a beta of 0.77.

VIVUS (NASDAQ:VVUS) last issued its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.13) by $0.07. The firm had revenue of $15.19 million for the quarter, compared to analysts’ expectations of $16.00 million. VIVUS had a return on equity of 344.23% and a net margin of 26.71%. The firm’s revenue for the quarter was up 13.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.09) EPS. research analysts forecast that VIVUS, Inc. will post -0.32 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “VIVUS, Inc. (VVUS) Stake Held by California Public Employees Retirement System” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/12/04/vivus-inc-vvus-stake-held-by-california-public-employees-retirement-system.html.

About VIVUS

VIVUS, Inc is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED).

Institutional Ownership by Quarter for VIVUS (NASDAQ:VVUS)

Receive News & Stock Ratings for VIVUS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS Inc. and related stocks with our FREE daily email newsletter.